DCT and neoplasm: These same mice were also challenged subcutaneously with live B16.F10 cells (1 × 105 cells per mouse) on day 14 after vaccination, and all three vaccination doses showed a protective phenotype with all control mice (100%, n = 5) succumbing to the tumor by day 20 posttumor challenge (PTC), while the mice vaccinated with 5 × 107, 1 × 108, and 5 × 108 PFUs of Ad5-TRP2 demonstrated 60, 60, and 80% TF survival at the termination of the experiment on day 55, respectively (Fig. 3B).